These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31503216)

  • 41. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.
    Vande Casteele N; Feagan BG; Wolf DC; Pop A; Yassine M; Horst SN; Ritter TE; Sandborn WJ
    Inflamm Bowel Dis; 2021 Jul; 27(8):1346-1355. PubMed ID: 33051647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy.
    Yao J; Jiang X; You JHS
    Inflamm Bowel Dis; 2021 Jan; 27(2):275-282. PubMed ID: 32311018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
    Nassar-Sheikh Rashid A; Schonenberg-Meinema D; Bergkamp SC; Bakhlakh S; de Vries A; Rispens T; Kuijpers TW; Wolbink G; van den Berg JM
    Pediatr Rheumatol Online J; 2021 Apr; 19(1):59. PubMed ID: 33926495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
    Bar-Yoseph H; Blatt A; Gerassy S; Pressman S; Mousa A; Sabo E; Waterman M; Ungar B; Ben-Horin S; Chowers Y
    J Crohns Colitis; 2022 Jul; 16(6):884-892. PubMed ID: 34849649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
    Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
    Anjie SI; Hulshoff MS; D'Haens G
    Expert Opin Biol Ther; 2023 Apr; 23(4):341-351. PubMed ID: 37010030
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty.
    Kochar BD; Cai W; Ananthakrishnan AN
    Dig Dis Sci; 2022 Feb; 67(2):622-628. PubMed ID: 33932198
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary.
    Kósa F; Kunovszki P; Borsi A; Iliás Á; Palatka K; Szamosi T; Vincze Á; Molnár T; Lakatos PL
    Dig Liver Dis; 2020 Mar; 52(3):274-280. PubMed ID: 31669077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
    de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
    J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Loss of response to anti-TNF therapy in inflammatory bowel disease: experience in a reference hospital in Lima - Peru].
    Paredes Méndez JE; Alosilla Sandoval PA; Vargas Marcacuzco HT; Mestanza Rivas Plata AL; Gonzá Les Yovera JG
    Rev Gastroenterol Peru; 2020; 40(1):22-28. PubMed ID: 32369462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease.
    Salvador-Martín S; Pujol-Muncunill G; Bossacoma F; Navas-López VM; Gallego-Fernández C; Segarra O; Clemente S; Muñoz-Codoceo R; Viada J; Magallares L; Martínez-Ojinaga E; Moreno-Álvarez A; Solar-Boga A; Loverdos I; Merino-Bohórquez V; Balboa-Vega MJ; Rodriguez-Martinez A; Alvarez-Vayo C; Sanchez C; Tolin M; Blanca-García JA; García-Romero R; Eizaguirre FJ; Sánchez-Hernandez JG; de Caldas RG; Millán-Jimenez A; Aznal E; Abarca-Zabalía J; Sanjurjo-Sáez M; López-Fernández LA
    Br J Clin Pharmacol; 2021 Feb; 87(2):447-457. PubMed ID: 32478906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study.
    Cheli S; Savino D; De Silvestri A; Norsa L; Sansotta N; Penagini F; Dilillo D; Panceri R; Cattaneo D; Clementi E; Zuin G
    Pharmacogenomics J; 2023 Sep; 23(5):112-118. PubMed ID: 37016150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
    Liu Z; Julsgaard M; Zhu X; Martin J; Barclay ML; Cranswick N; Gibson PR; Gearry RB; van der Giessen J; Connor SJ; Rosella O; Grosen A; Toong C; Flanagan E; Wieringa JW; Janneke van der Woude C; Bell SJ;
    J Crohns Colitis; 2022 Dec; 16(12):1835-1844. PubMed ID: 35779236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.
    Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S
    Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.